Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis

References

Page 1

	Year	Citations
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials Richard G. Langley, Boni E. Elewski, Mark Lebwohl, New England Journal of Medicine	2014	1.9K
Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis Yan Zheng, Dimitry M. Danilenko, Patricia Valdez, Nature InflammationCytokineIl-23-induced Dermal InflammationAutoimmune DiseaseImmunology	2006	1.8K
Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways Kristine Nograles, Lisa C. Zaba, Emma Guttman‐Yassky, British Journal of Dermatology	2008	795
Guidelines of care for the management of psoriasis and psoriatic arthritis Alan Menter, Neil J. Korman, Craig A. Elmets, Journal of the American Academy of Dermatology RheumatologyMedicineClinical DermatologyDermatologyPsoriatic Arthritis	2009	474
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial H. Bachelez, P.C.M. van de Kerkhof, Robert Strohal, The Lancet Autoimmune DiseaseClinical TrialsInflammatory MarkerClinical DermatologyTofacitinib Versus	2015	388
Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans Susan Smith, Channa Jayawickreme, David J. Rickard, Journal of Investigative Dermatology InflammationNatural Ahr AgonistAnti-inflammatoryAutoimmune DiseaseMedicine	2017	351
Activation of the Aryl Hydrocarbon Receptor Dampens the Severity of Inflammatory Skin Conditions Paola Di Meglio, João H. Duarte, Helena Ahlfors, Immunity	2014	348
Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways G.M.P. Galbraith Yearbook of Dermatology and Dermatologic Surgery InflammationCytokineImmune RegulationImmunologyChronic Inflammation	2009	167
Autoantigens <scp>ADAMTSL</scp>5 and <scp>LL</scp>37 are significantly upregulated in active Psoriasis and localized with keratinocytes, dendritic cells and other leukocytes Judilyn Fuentes‐Duculan, Kathleen M. Bonifacio, Jason E. Hawkes, Experimental Dermatology	2017	113
Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial Robert Bissonnette, Yves Poulin, Yabo Zhou, British Journal of Dermatology	2011	92

Page 1